Dr. Reddy’s Canada Semaglutide Launch: First G7 NOC

What Dr. Reddy’s launched, and why it matters

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) has launched its generic Semaglutide Injection in Canada on May 15, 2026. The launch follows a Notice of Compliance (NOC) from Health Canada dated April 28, 2026. The company has positioned the development as a key step in its GLP-1 therapy strategy, as semaglutide is a widely used GLP-1 receptor agonist for type 2 diabetes. Canada is also the first G7 country to grant market authorisation for a generic semaglutide injection, giving the approval added significance for global generic timelines. Dr. Reddy’s has said it is among the first to introduce a generic semaglutide injection in the Canadian market. The move extends the company’s earlier semaglutide rollout in India under the brand name Obeda®.

Regulatory milestone: Health Canada’s Notice of Compliance

Health Canada granted the NOC for Dr. Reddy’s generic Semaglutide Injection ahead of the regulator’s review target date, according to the company’s communication. Dr. Reddy’s has described itself as the first company to receive market authorisation for generic Semaglutide Injection in Canada. This matters because regulatory clearances in highly regulated markets often serve as reference points for manufacturing readiness and dossier strength. The approval covers two pen presentations of semaglutide at the same concentration. Following the approval, Dr. Reddy’s stated that launch preparations were underway, culminating in the May 15, 2026 introduction. Health Canada separately described the authorisation as the first generic semaglutide approved by the agency and the first approved in the G7.

Product format and dosing: pre-filled pens for once-weekly use

Dr. Reddy’s generic Semaglutide Injection is supplied as a sterile solution for subcutaneous injection in a pre-filled pen. It is available in 2 mg/pen and 4 mg/pen strengths, each at a concentration of 1.34 mg/mL. The company’s product information indicates that the 2 mg/pen presentation delivers 0.25 mg or 0.5 mg doses, while the 4 mg/pen delivers 1 mg doses. The medicine is indicated for once-weekly treatment of adults with type 2 diabetes mellitus to improve glycaemic control in combination with diet and exercise. The indication language also outlines use across multiple treatment settings, including alongside metformin, sulfonylureas, SGLT2 inhibitors, and basal insulin with metformin. At the same time, the disclosures state that semaglutide injection is not a substitute for insulin.

What the label limitations say

The company has stated that semaglutide has not been studied in combination with prandial (short-acting) insulin. It also states that the injection should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. These limitations matter for patient selection and prescribing, especially in a market where GLP-1 usage has expanded rapidly. In its announcement, Dr. Reddy’s linked the launch to its broader focus on GLP-1 therapies as an important segment. The Canadian introduction adds a regulated-market reference for the firm’s peptide-based, complex generics portfolio.

Manufacturing and supply chain: in-house API, partner-led finished product

Dr. Reddy’s has said the active pharmaceutical ingredient (API) for the Canadian product is manufactured entirely in-house. Finished product manufacturing is being supported by OneSource Specialty Pharma Limited, which is serving as the contract development and manufacturing organisation (CDMO) partner for the programme. OneSource is expected to provide scale-up and commercial manufacturing support from its US FDA-approved manufacturing facility in Bengaluru, according to the statement cited. This division of responsibilities is notable because peptide APIs and device-based injectables require consistent process control and validated manufacturing systems. The company has framed the approval as a proof point of capability in complex generics and peptide-based medicines.

Canada as the first G7 authorisation: what that signals

The company and Health Canada have emphasised that Canada is the first G7 market to authorise a generic semaglutide injection. Dr. Reddy’s has described Canada as the world’s second-largest market for semaglutide, underlining why early entry there is strategically important. Management also pointed to an established commercial footprint and market access capabilities in Canada. While the company did not disclose pricing in the materials provided, it described the effort as part of expanding access to high-quality, affordable GLP-1 treatments for patients with diabetes in the country. The approval and launch together give Dr. Reddy’s an early presence in a G7 market for an in-demand diabetes therapy category.

Link to India launch: Obeda® and the broader rollout plan

The Canadian launch builds on Dr. Reddy’s earlier semaglutide introduction in India under the brand name Obeda®. The company has said it plans to expand both oral and injectable semaglutide formulations across all global markets. In India, Novo Nordisk’s patent expiry for semaglutide was cited as March 20, 2026, after which generic launches became possible. Another India-specific detail flagged in the provided material is that generic semaglutide products do not feature on India’s National List of Essential Medicines, implying out-of-pocket purchase dynamics in that market. Together, the India and Canada milestones show a strategy of pairing domestic launches with regulated-market approvals.

Key facts at a glance

Market impact: what is known from the announcement

From an India-listed pharma perspective, the development is relevant because it is tied to a large, fast-growing GLP-1 segment and comes with a first-in-G7 authorisation claim. The company’s disclosures focus on regulatory and manufacturing readiness rather than commercial numbers, and they do not include revenue guidance or pricing. What is concrete is the sequence: a Health Canada NOC (April 28, 2026), followed by a Canada launch (May 15, 2026), and the positioning of Canada as the first G7 authorisation for a generic semaglutide injection. The announcement also establishes the supply chain: in-house API production and partner-led finished product manufacturing. For investors tracking execution in complex generics, these details help evaluate whether the company can scale peptide-based injectables across regulated markets.

Why this matters for Dr. Reddy’s GLP-1 strategy

Semaglutide’s category importance is reflected in Dr. Reddy’s repeated emphasis on GLP-1 therapies as a focus area. The company has also highlighted that the authorisation arrived ahead of Health Canada’s review target date, suggesting smoother-than-expected regulatory closure. Operationally, the use of a CDMO partner for formulation manufacturing alongside in-house API production indicates a model designed to support scale-up and commercial supply. Dr. Reddy’s has communicated intent to extend both oral and injectable semaglutide formats globally, using its India launch and Canada authorisation as steps in that plan. The Canadian approval also signals that an India-manufactured API and associated dossier have met Health Canada’s standards.

Closing summary and what to watch next

Dr. Reddy’s Canada launch of generic Semaglutide Injection on May 15, 2026 follows a Health Canada NOC dated April 28, 2026 and marks the first G7 authorisation for a generic semaglutide injection. The product is supplied as once-weekly pre-filled pens in 2 mg/pen and 4 mg/pen strengths at 1.34 mg/mL, with stated dose options of 0.25 mg, 0.5 mg, and 1 mg. The company has linked the launch to its broader GLP-1 strategy, supported by in-house API manufacturing and partner-backed finished product manufacturing. Next, investors will watch for further country filings or launches as Dr. Reddy’s pursues expansion of both oral and injectable semaglutide across global markets.